<?xml version='1.0' encoding='utf-8'?>
<document id="26068527"><sentence text="Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats."><entity charOffset="10-21" id="DDI-PubMed.26068527.s1.e0" text="fluvoxamine" /><entity charOffset="70-81" id="DDI-PubMed.26068527.s1.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26068527.s1.e0" e2="DDI-PubMed.26068527.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26068527.s1.e0" e2="DDI-PubMed.26068527.s1.e1" /></sentence><sentence text="1" /><sentence text=" Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is often coprescribed with clopidogrel for the treatment of ischemic vascular diseases"><entity charOffset="1-12" id="DDI-PubMed.26068527.s3.e0" text="Fluvoxamine" /><entity charOffset="26-35" id="DDI-PubMed.26068527.s3.e1" text="serotonin" /><entity charOffset="90-101" id="DDI-PubMed.26068527.s3.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26068527.s3.e0" e2="DDI-PubMed.26068527.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26068527.s3.e0" e2="DDI-PubMed.26068527.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26068527.s3.e0" e2="DDI-PubMed.26068527.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26068527.s3.e1" e2="DDI-PubMed.26068527.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26068527.s3.e1" e2="DDI-PubMed.26068527.s3.e2" /></sentence><sentence text=" The aim of this study was to explore the effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel"><entity charOffset="52-63" id="DDI-PubMed.26068527.s4.e0" text="fluvoxamine" /><entity charOffset="112-123" id="DDI-PubMed.26068527.s4.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26068527.s4.e0" e2="DDI-PubMed.26068527.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26068527.s4.e0" e2="DDI-PubMed.26068527.s4.e1" /></sentence><sentence text=" 2" /><sentence text=" Twelve male rats were employed to investigate the effect of fluvoxamine on the pharmacokinetics of clopidogrel in vivo"><entity charOffset="61-72" id="DDI-PubMed.26068527.s6.e0" text="fluvoxamine" /><entity charOffset="100-111" id="DDI-PubMed.26068527.s6.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26068527.s6.e0" e2="DDI-PubMed.26068527.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26068527.s6.e0" e2="DDI-PubMed.26068527.s6.e1" /></sentence><sentence text=" Clopidogrel carboxylic acid was used for the pharmacokinetic study of clopidogrel"><entity charOffset="1-28" id="DDI-PubMed.26068527.s7.e0" text="Clopidogrel carboxylic acid" /><entity charOffset="71-82" id="DDI-PubMed.26068527.s7.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26068527.s7.e0" e2="DDI-PubMed.26068527.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26068527.s7.e0" e2="DDI-PubMed.26068527.s7.e1" /></sentence><sentence text=" 3" /><sentence text=" After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p&lt;0"><entity charOffset="38-49" id="DDI-PubMed.26068527.s9.e0" text="fluvoxamine" /></sentence><sentence text="05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p&lt;0" /><sentence text="05) and t1/2 (from 2" /><sentence text="07±0" /><sentence text="0942 to 7" /><sentence text="49±1" /><sentence text="22 h; p&lt;0" /><sentence text="05) of clopidogrel carboxylic acid"><entity charOffset="7-34" id="DDI-PubMed.26068527.s16.e0" text="clopidogrel carboxylic acid" /></sentence><sentence text=" The pharmacokinetic data for clopidogrel carboxylic acid showed significant decreases in VLz/F (from 0"><entity charOffset="30-57" id="DDI-PubMed.26068527.s17.e0" text="clopidogrel carboxylic acid" /></sentence><sentence text="765±0" /><sentence text="299 to 0" /><sentence text="256±0" /><sentence text="0594 l/kg; p&lt;0" /><sentence text="05) after pretreatment with high dose of fluvoxamine"><entity charOffset="41-52" id="DDI-PubMed.26068527.s22.e0" text="fluvoxamine" /></sentence><sentence text=" Pharmacodynamic studies that measure platelet aggregation percentage (from 21" /><sentence text="63±6" /><sentence text="05% to 45" /><sentence text="98±5" /><sentence text="11%; p&lt;0" /><sentence text="01) show that high doses of fluvoxamine significantly inhibit the effect of clopidogrel"><entity charOffset="28-39" id="DDI-PubMed.26068527.s28.e0" text="fluvoxamine" /><entity charOffset="76-87" id="DDI-PubMed.26068527.s28.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26068527.s28.e0" e2="DDI-PubMed.26068527.s28.e0" /><pair ddi="false" e1="DDI-PubMed.26068527.s28.e0" e2="DDI-PubMed.26068527.s28.e1" /></sentence><sentence text=" 4" /><sentence text=" In conclusion, the pharmacokinetics and pharmacodynamics of clopidogrel were significantly affected by high doses of fluvoxamine"><entity charOffset="61-72" id="DDI-PubMed.26068527.s30.e0" text="clopidogrel" /><entity charOffset="118-129" id="DDI-PubMed.26068527.s30.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.26068527.s30.e0" e2="DDI-PubMed.26068527.s30.e0" /><pair ddi="false" e1="DDI-PubMed.26068527.s30.e0" e2="DDI-PubMed.26068527.s30.e1" /></sentence><sentence text=" This study indicated that potential drug-drug interaction between fluvoxamine and clopidogrel should be taken into consideration in clinical use"><entity charOffset="67-78" id="DDI-PubMed.26068527.s31.e0" text="fluvoxamine" /><entity charOffset="83-94" id="DDI-PubMed.26068527.s31.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26068527.s31.e0" e2="DDI-PubMed.26068527.s31.e0" /><pair ddi="false" e1="DDI-PubMed.26068527.s31.e0" e2="DDI-PubMed.26068527.s31.e1" /></sentence><sentence text="" /></document>